German university hospital strong in immunotherapy, cancer biomarkers, and computational neuroscience through the Human Brain Project.
Freiburg University Medical Center is a major German teaching hospital that combines clinical care with deep research in immunology, cancer biology, neuroscience, and advanced therapies. Their H2020 portfolio shows strong capabilities in CAR-T cell therapy, gene therapy, autophagy research, and brain simulation/neuroinformatics through the Human Brain Project. They bridge bench-to-bedside translation — from molecular mechanisms (protease research, genome editing) to clinical trials (bone regeneration, skeletal dysplasia drug repurposing, stroke). Their work spans rare diseases, immune disorders like graft-versus-host disease, and digital health monitoring for neurological conditions.
Coordinator of GvHDCure (graft-versus-host disease), participant in CARAT (CAR-T cells), ALKATRAS (cancer), SCIDNET (gene therapy for SCID), TRAIN-EV (extracellular vesicles in inflammation), and ApoptoMDS (bone marrow failure).
Sustained participation in Human Brain Project (HBP SGA1, SGA2), ICEI computing infrastructure, and coordinator of IN-Fo-trace-DG on dentate gyrus memory formation, plus HOLOBALANCE.
Coordinator of HEP-CAR (hepatocellular carcinoma), participant in BEAt-DKD (biomarkers), DRIVE (autophagy), TRAIN-EV (cancer biomarkers), MCDS-Therapy, and ALKATRAS.
Coordinator of AutoClean (cell-free autophagy reconstitution, EUR 1.96M ERC grant), MITOsmORFs (mitochondrial proteins), participant in DRIVE (autophagy) and PoLiMeR (liver metabolism).
Participant in MCDS-Therapy (carbamazepine repurposing), ORTHOUNION (bone regeneration RCT), PAPA-ARTIS (paraplegia prevention RCT), BIO-CHIP (cartilage), and CIRDinnova (resuscitation device).
Participant in RADAR-CNS (wearable remote monitoring for MS/epilepsy/depression), DynaMORE (ecological momentary assessment for resilience), and HOLOBALANCE (AR-based physiotherapy).
In the early period (2015–2018), Freiburg focused heavily on cancer biology, immunotherapy, and molecular medicine — hepatocellular carcinoma, CAR-T cells, gene therapy, inflammation biomarkers, and personalized therapy dominated their keyword landscape. From 2018 onward, a clear shift toward computational neuroscience emerged: brain simulation, neuroinformatics, neuromorphic computing, neurorobotics, and optogenetics became prominent through the Human Brain Project and the IN-Fo-trace-DG project. This evolution reflects a move from primarily molecular/cellular immunology toward large-scale brain research and digital health tools, while maintaining their immunology core.
Freiburg is expanding from its immunology/oncology base into computational neuroscience and digital health monitoring, making them increasingly relevant for interdisciplinary projects combining clinical medicine with data science and HPC.
With 15 coordinated projects out of 50, Freiburg takes the lead in nearly a third of their projects — a high coordination rate for a university hospital, signaling strong project management capacity. They operate across a wide network of 600 unique partners in 39 countries, indicating they function as a hub rather than returning to the same partners. Their mix of large consortia (RIA projects, Human Brain Project) and focused ERC grants shows they are equally comfortable leading small investigator-driven research and contributing specialized expertise to massive multi-partner initiatives.
Freiburg has collaborated with 600 unique partners across 39 countries, making them one of the more broadly connected university hospitals in H2020. Their network spans nearly all of Europe with strong ties to health research, neuroscience, and clinical trial consortia.
Freiburg combines clinical hospital infrastructure with fundamental research at an unusually high level — they can run clinical trials, do molecular biology, AND contribute to computational neuroscience projects requiring HPC expertise. Their dual strength in immunology/oncology and brain research (via the Human Brain Project) is rare for a single institution and makes them a versatile consortium partner. With 15 coordinated projects and EUR 27.5M in EC funding, they have proven grant management capacity that de-risks partnerships.
